- Home
- MESO vs ARR Comparison
MESO vs ARR Comparison
Compare MESO & ARR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MESO | ARR |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 2005 | 2009 |
Fundamental Metrics
Financial Performance| Metric | MESO | ARR |
|---|---|---|
| Price | $13.68 | $12.20 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $37.00 | $15.56 |
| AVG Volume (30 Days) | 255.3K | ★ 4.6M |
| Earning Date | 08-26-2026 | 10-21-2026 |
| Dividend Yield | N/A | ★ 23.70% |
| EPS Growth | N/A | ★ 747.06 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $51.63 | N/A |
| Revenue Next Year | $63.39 | $18.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.89 | $12.02 |
| 52 Week High | $21.50 | $19.31 |
Technical Indicators
Market Signals| Indicator | MESO | ARR |
|---|---|---|
| Relative Strength Index (RSI) | 46.52 | 34.95 |
| Support Level | $11.89 | $12.15 |
| Resistance Level | $16.03 | $17.72 |
| Average True Range (ATR) | 0.50 | 0.35 |
| MACD | 0.07 | 0.06 |
| Stochastic Oscillator | 40.72 | 20.82 |
Price Performance
Historical ComparisonAbout MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
About ARR ARMOUR Residential REIT Inc.
ARMOUR Residential REIT Inc operate in the U.S. and invest in fixed rate residential, adjustable rate and hybrid adjustable rate residential MBS issued or guaranteed by U.S. GSEs or guaranteed by Ginnie Mae. It also invest in U.S. Treasury Securities and money market instruments.